Novo Nordisk to Soon File for Approval to Sell Wegovy Pill in China

According to Reuters, Novo Nordisk plans to file a regulatory approval application shortly to market the pill form of its obesity drug Wegovy in China. The company aims to address the growing obesity problem in China with this move. Novo Nordisk seeks to improve patient access to treatment by developing a pill version of Wegovy alongside its injectable form. China, as one of the world's largest pharmaceutical markets, holds strategic importance for the company. Company officials stated that if the Wegovy pill is approved in China, the product could reach a broad patient population and fill a significant gap in obesity treatment. However, the timeline for the approval process and the conditions for its sale have not yet been clarified. This move by Novo Nordisk could intensify competition in China's obesity drug market. The company expects the pill form of Wegovy to offer easier administration and lower cost advantages compared to the injectable version. This is not investment advice.